Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 46.42M shares rose 9.0% year over year, ahead of the +7.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +9.0% holds above the trailing-twelve-month pace of +7.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
46.42M+7.0% QoQ
Last fiscal yearDec 2025
41.78M+11.1% YoY
LTMSep 2026
43.89M+7.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+9.0%——
1 year+11.1%——
3-year CAGR+19.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
41.78M USD
Year-over-year change
+11.1%
4-year CAGR
+19.4%

Weighted Avg Shares (Diluted) vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's LTM Sep 2026 weighted avg shares (diluted) of 43.89M shares is the 2nd highest of the 6 companies compared; the peer median is 25.17M shares.
  • Its year-over-year change of +7.8% is the 2nd highest of 5, against a peer median of +6.6%.
  • Over three fiscal years its annual growth of +19.3% compares with a peer median of +21.2%.
TARS Competitors Peer median
Weighted Avg Shares (Diluted) for TARS and competitors
Company Period LTM YoY 3-year CAGR
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026133.45M +7.1%+32.2%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 202643.89M +7.8%+19.3%
HROWHarrow Health, Inc.LTM Mar 202637.93M +6.1%+10.2%
TTRXTurn Therapeutics Inc.LTM Mar 202625.17M ——
VRCAVerrica Pharmaceuticals Inc.LTM Mar 202610.07M +57.7%+46.1%
SLGLSol-Gel Technologies Ltd.LTM Mar 20262.8M -90.0%-50.6%
Peer median (excluding TARS) 25.17M+6.6%+21.2%

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue57.03M25.82M17.45M182.95M451.36M
Cost of Revenue2.08M955K1.59M12.83M30.68M
Gross Profit54.95M24.86M15.85M170.13M420.68M
Gross Margin96.4%96.3%90.9%93.0%93.2%
Research & Development41.71M42.62M50.31M53.39M64.32M
Selling, General & Admin25.4M44.95M108.7M237.31M427.32M
Operating Expenses67.11M87.57M159.01M290.7M491.65M
Depreciation & Amortization312K326K877K1.23M1.82M
EBITDA(13.46M)(59.71M)(131.67M)(106.48M)(53.61M)
EBITDA Margin-23.6%-231.3%-754.7%-58.2%-11.9%
Operating Income(12.16M)(62.71M)(143.16M)(120.57M)(70.97M)
Operating Margin-21.3%-242.9%-820.5%-65.9%-15.7%
Interest Income36K3.5M10.34M15.01M15.75M
Interest Expense02.06M3.23M7.45M8.94M
Other Income / Expenses(1.62M)617K7.27M5.02M6.61M
Income Before Tax(13.77M)(62.1M)(135.89M)(115.55M)(64.36M)
Pre-Tax Margin-24.1%-240.5%-778.9%-63.2%-14.3%
Income Tax Expense55K(4K)002.06M
Net Income(13.83M)(62.09M)(135.89M)(115.55M)(66.42M)
Net Margin-24.2%-240.5%-778.9%-63.2%-14.7%
EPS (Basic)(0.67)(2.52)(4.62)(3.07)(1.59)
EPS (Diluted)(0.67)(2.52)(4.62)(3.07)(1.59)
Weighted Avg Shares20.55M24.62M29.38M37.6M41.78M
Weighted Avg Shares (Diluted)20.55M24.62M29.38M37.6M41.78M

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.